Shares in Valeant Pharmaceuticals (NYSE:VRX) rose more than 25% today after the company met earnings expectations on Wall Street, but missed on revenue with its 1st quarter results.
The Canada-based company posted profits of $628 million, or $1.79 per share, on sales of $2.11 billion for the 3 months ended March 31, for bottom-line growth of 267% on sales loss of -11% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeant posts Q1 profit thanks to tax benefit, misses on revenue appeared first on MassDevice.